Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Higher-dose weight loss injections now available ... demonstrated remarkable outcomes for patients using the higher-dose semaglutide. Participants experienced an average of 20.7% total body ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

New Delhi: The Telangana Medical Council has taken suo moto cognisance of case wherein a minor patient died within seconds after being given an injection at a Thorrur-based nursing home. Taking note ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type ... or appropriate for all patients or all specific uses.

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with ... 20 mL every four weeks injection for IV infusion ...

A variety of approved and experimental lipid-lowering agents may be used as supplements or alternatives to statin therapy in patient subgroups, including those with familial hypercholesterolemia ...